Pontifax Venture Capital — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Nuvectisnuvectis.comin𝕏Jul 2022
Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma.
BiotechHealthtechFort Lee, US
James Oliviero(Director)Enrique Poradosu(Executive Officer)Matthew Kaplan(Director)Michael Carson(Executive Officer)Kenneth Hoberman(Director)Ron Bentsur(Executive Officer, Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.